Gilead failed, but Intercept succeeded

Discussion in 'Gilead Sciences' started by anonymous, Feb 19, 2019 at 10:21 AM.


  1. anonymous

    anonymous Guest

    Call that a success for Intercept? The product will only be used if paired with another product. Too much risk and too little improvement for insurers to jump on it if it gets approved with the black box warning.
    Best to call it a start on a long journey toward optimization of therapy